Pipeline: Presbyopia treatment to finish Phase 3 late 2021

Video
Conference|Vision Expo East

Orasis Pharmaceuticals drop in development for treating presbyopia

Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.

Recent Videos
Steven T. Reed, OD, talks Optometry's Meeting and public-facing initiatives that optometrists can take advantage of.
The Vision Council CEO Ashley Mills overviews what is new and exciting at this year's show, running from February 19-22 in Orlando, Florida, and provides a free registration code for those still looking to register.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, discusses diagnostic confusion that can be encountered when identifying macular edema in patients.
ODs share what they learned at this year's Academy meeting and what they plan to take home to their practices.
Dana Shannon, OD, FAAO, details The Contact Lens Instiute's latest report, The Dropout Dilemma.
Billy R. Hammond details the study, which explored how HEV-light filtering, specifically in the 380-440 nanometer range, impacts visual comfort for patients with presbyopia.
Steve Ferrucci, OD, FAAO, discussed the detection and treatment of geographic atrophy during his AAOpt 2024 lecture, "Imaging Techniques and Emerging Therapies for Geographic Atrophy."
Related Content
The formulation of presbyopia-correcting drops makes a difference is comfort and usability - Image credit: Adobe Stock / ©Andrey Nikitin

The science of formulation: Advancing presbyopia treatment through optimized design

Jacob R. Lang, OD, FAAO;Jaclyn Garlich, OD, FAAO
March 13th 2025
Article
Practical management EP 14: Your practice-purchase checklist

Practical management EP 14: Your practice-purchase checklist

Maria Sampalis, OD;Kassi Jackson Filkins, Editor
April 27th 2023
Podcast
Charissa lee, OD, MBA, FAAO; Ryane Corte, OD; Roxanne Achong-Coan OD, FAAO, FIAOMC, FSLS, Dip CCLRT; and Nishan Pressley, OD; give their insights on recent Contact Lens Institute research on contact lens purchase factors and Google searches.

Vision Expo East 2025: An exclusive Q&A with CLI panelists on recent research – Part 1

Jordana Joy, Associate Editor;Charissa Lee, OD, MBA, FAAO;Ryan Corte, OD;Nishan Pressley, OD;Roxanne Achong-Coan, OD, FAAO, FIAOMC, FSLS, Dip CCLRT
March 5th 2025
Article
Jill Saxon, OD, executive director of professional strategy at Bausch + Lomb

Community care: Connecting mentorship and representation

Emily Kaiser Maharjan, Assistant Managing Editor
April 26th 2023
Podcast
Man driving at night Image credit: AdobeStock/Artem

Opus Genetics provides FDA Fast Track, enrollment updates on phentolamine ophthalmic solution 0.75% programs

Jordana Joy, Associate Editor
February 27th 2025
Article
closeup of eye during study of patients with glaucoma and presbyopia - Image credit: Adobe Stock / ©TensorSpark

Early presbyopia noted in patients treated with FP receptor agonists for glaucoma

Lynda Charters
February 11th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.